{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:27:31Z","timestamp":1792182451882,"version":"4.4.0"},"reference-count":72,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Patient-reported outcome measures (PROMs) are often used to evaluate the impact of treatment and clinical decisions on the patient experience for patients with lymphoma. Regulatory agencies have provided guidance on the use of PROMs for patient-focused drug development. Though PROMs are increasingly utilized, the way in which they are used, analyzed, and reported is heterogeneous. This systematic evidence-based review will focus on how PROMs are currently used for patients with lymphoma, what domains PROMs measure, their clinical significance, links to clinical outcomes, and what gaps need to be filled to better incorporate PROMs as endpoints in clinical trials and clinical decision-making.<\/jats:p>","DOI":"10.3390\/curroncol32050265","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:49:02Z","timestamp":1746082142000},"page":"265","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient-Reported Outcome Measures (PROMS) in Lymphoma"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7237-3530","authenticated-orcid":false,"given":"Neha","family":"Akkad","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology Fellowship Program, UT MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, UT MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_3","first-page":"740","article-title":"Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients","volume":"111","author":"Marino","year":"2020","journal-title":"Recent. Progress. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.2196\/jmir.7079","article-title":"\u201cAm I normal?\u201d The Wishes of Patients with Lymphoma to Compare Their Patient-Reported Outcomes with Those of Their Peers","volume":"19","author":"Oerlemans","year":"2017","journal-title":"J. Med. Internet Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1080\/10428194.2019.1632446","article-title":"Experts on their own experiences: The rise of patient-reported outcomes in oncology drug trials","volume":"60","author":"LeBlanc","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_7","unstructured":"FDA (2022). Patient-Focused Drug Development: Methods to Identify What is Important to Patients. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders."},{"key":"ref_8","unstructured":"FDA (2022). Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-forPurpose Clinical Outcome Assessments Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders."},{"key":"ref_9","unstructured":"FDA (2020). Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101953","DOI":"10.1016\/j.eclinm.2023.101953","article-title":"Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017\u20132022","volume":"59","author":"Ge","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5195\/jmla.2021.962","article-title":"PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"109","author":"Rethlefsen","year":"2021","journal-title":"J. Med. Libr. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2414425","DOI":"10.1001\/jamanetworkopen.2024.14425","article-title":"Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e9869904","DOI":"10.1097\/01.HS9.0000973644.98699.04","article-title":"P1693: Patient-Reported Outcomes in Lymphoma Trials: A Systematic Review","volume":"7","author":"Laane","year":"2023","journal-title":"Hemasphere"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/10428194.2019.1602262","article-title":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma","volume":"60","author":"Fanale","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/0959-8049(95)00296-0","article-title":"The EORTC core quality of life questionnaire (QLQ-C30): Validity and reliability when analysed with patients treated with palliative radiotherapy","volume":"31","author":"Kaasa","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events with the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the Functional Assessment of Cancer Therapy\u2013Lymphoma (FACT-LYM) in Patients with Relapsed\/Refractory Mantle Cell Lymphoma","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology.","DOI":"10.1037\/e591322011-001"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s41687-024-00752-6","article-title":"Content validation of the National Comprehensive Cancer Network\/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin's lymphoma","volume":"8","author":"Hurt","year":"2024","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness","volume":"107","author":"Chren","year":"1996","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.18072","article-title":"International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia","volume":"197","author":"Oerlemans","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study","volume":"17","author":"Huang","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med. Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2340\/00015555-1265","article-title":"Visual analogue scale: Evaluation of the instrument for the assessment of pruritus","volume":"92","author":"Reich","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy 2013; Leukemia (FACT-Leu) Questionnaire","volume":"15","author":"Cella","year":"2012","journal-title":"Value Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147176","DOI":"10.1155\/2013\/147176","article-title":"The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin\u2019s Lymphoma: The Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Balitsky, A., Pond, G.R., Davies, G.A., Fraser, G., Kouroukis, T., Levine, M., Meyer, R.M., and Foley, R. (2024). Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12574-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2023.283162","article-title":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: Patient-reported outcomes from the PILOT study","volume":"109","author":"Gordon","year":"2024","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clml.2023.11.005","article-title":"Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated with Epcoritamab","volume":"24","author":"Phillips","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1080\/03007995.2024.2409837","article-title":"Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: Results from the ROSEWOOD trial","volume":"40","author":"Trotman","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1007\/s12325-024-02882-1","article-title":"Quality of Life Evaluation in Patients with Follicular Cell Lymphoma: A Real-World Study in Europe and the United States","volume":"41","author":"Johnson","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients with Cutaneous T-cell Lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","article-title":"Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study","volume":"133","author":"Dummer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2024-194796","article-title":"Health-Related Quality of Life in Patients with Relapsed\/Refractory Cutaneous T-Cell Lymphoma Treated by Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial","volume":"144","author":"Bagot","year":"2024","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1320","DOI":"10.1200\/OP.21.00789","article-title":"Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients with Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared with Standard Care","volume":"18","author":"Sidana","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1069","DOI":"10.1200\/OP.21.00694","article-title":"Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients with Aggressive Lymphoma: A Prospective Cohort Analysis","volume":"18","author":"Strouse","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3324\/haematol.2021.280413","article-title":"Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life","volume":"107","author":"Smeland","year":"2022","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e006959","DOI":"10.1136\/jitc-2023-006959","article-title":"Patient-reported outcomes in CD30-directed CAR-T cells against relapsed\/refractory CD30+ lymphomas","volume":"11","author":"Tschernia","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","first-page":"1219.e1211","article-title":"Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy","volume":"30","author":"Hoogland","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2014.57.6801","article-title":"Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: Results from ECOG trial E4402 (RESORT)","volume":"33","author":"Wagner","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1080\/10428194.2022.2123225","article-title":"Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance","volume":"63","author":"Major","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: Results of a prospective randomized controlled trial","volume":"88","author":"Reiz","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_49","unstructured":"(2024, September 03). Cancer Stat Facts: NHL\u2014Diffuse Large B-Cell Lymphoma (DLBCL), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2016.01.001","article-title":"Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP\/R-CVP in Patients with Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","volume":"16","author":"Burke","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_51","first-page":"147","article-title":"Quality of Life in Relapsed\/Refractory Mantle Cell Lymphoma Patients Treated with Lenalidomide Vs Investigator\u2019s Choice: MCL-002 (SPRINT) Trial","volume":"100","author":"Rule","year":"2015","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1080\/10428194.2017.1326034","article-title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","volume":"58","author":"Hess","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e34270c34275","DOI":"10.1097\/01.HS9.0000971344.34270.c5","article-title":"P1112: Patient-Reported Outcomes (Pro) Among Patients with Mantle Cell Lymphoma Receiving Pirtobrutinib After Prior Covalent Btki: Interim Pro Analysis from the Bruin Phase 1\/2 Study","volume":"7","author":"Cohen","year":"2023","journal-title":"HemaSphere"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jdv.16021","article-title":"Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and S\u00e9zary syndrome: Comparison of generic and dermatology-specific instruments","volume":"34","author":"Herbosa","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/jdv.17570","article-title":"Quality of life in patients with Mycosis Fungoides and S\u00e9zary Syndrome: A systematic review of the literature","volume":"35","author":"Ottevanger","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ottevanger, R., van Beugen, S., Evers, A.W.M., Willemze, R., Vermeer, M.H., and Quint, K.D. (2022). Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider. Cancers, 15.","DOI":"10.3390\/cancers15010032"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator","volume":"9","author":"Ottevanger","year":"2022","journal-title":"JAAD Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hon.2522","article-title":"Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma","volume":"36","author":"Thompson","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00277-012-1516-0","article-title":"Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study","volume":"91","author":"Jung","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cam4.4692","article-title":"Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-024-00708-w","article-title":"Are changes in patient-reported outcomes prognostic for diffuse large B-Cell lymphoma survival? Results from the GOYA trial","volume":"8","author":"Yan","year":"2024","journal-title":"J. Patient. Rep. Outcomes"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","article-title":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","volume":"59","author":"Gwaltney","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12955-019-1121-1","article-title":"Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings","volume":"17","author":"Mesa","year":"2019","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/14796694.2024.2357537","article-title":"End points in clinical trials in diffuse large B-cell lymphoma: Time for more dialogue?","volume":"20","author":"Degtyarev","year":"2024","journal-title":"Future Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(22)00021-3","article-title":"Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials","volume":"23","author":"Fiero","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41687-024-00683-2","article-title":"Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library","volume":"8","author":"Markowitz","year":"2024","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjd.19298","article-title":"Current measures are not sufficient: An interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma","volume":"184","author":"Bhat","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e11302","DOI":"10.2196\/11302","article-title":"Measurement of Quality of Life in Patients with Mycosis Fungoides\/S\u00e9zary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument","volume":"21","author":"McCaffrey","year":"2019","journal-title":"J. Med. Internet Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/265\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:25:53Z","timestamp":1760030753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050265"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050265","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}